PubMed Triage Digest — 2026-08-01
Run: 2026-08-01T09:00:00Z · Window: 2026-07-31 → 2026-08-01 · Attempt 1 of 3 Coverage: 9 topics queried · 118 candidates reviewed · 10 HIGH · 22 MEDIUM · 7 LOW Notable gap: T2 (CBC/ML) — zero results on both primary and fallback queries.
🔴 HIGH PRIORITY (score ≥ 7)
Aging & Longevity
[42538566] Merino LG et al. · Genome Med · 2026-07-31 · Score: 9
Single-cell analysis of the progeria arterial wall reveals progerin-induced progressive, cell type-specific dysfunction and somatic mutation accumulation.
First single-cell atlas of HGPS arterial disease (LmnaG609G/G609G mouse model). scRNA-seq of aortic arch identifies cell-type-specific progerin-induced dysfunction and somatic mutation accumulation. Reveals conserved aging niche programs with potential relevance to normal cardiovascular aging. Topic: aging_longevity · study: scRNA-seq · species: HGPS mouse · evidence: preclinical
Hematologic Malignancies
[42538429] Liao C et al. · Leukemia · 2026-07-31 · Score: 8
Targeting ACSF2 overcomes Ara-C resistance in acute myeloid leukemia via the cholesterol metabolism-ERK signaling axis.
Novel metabolic target for Ara-C-resistant AML. ACSF2 inhibition impairs cholesterol esterification → mitochondrial dysfunction → suppressed ERK → restored cytarabine sensitivity. SREBF1 inhibitor fatostatin synergizes with Ara-C in R/R AML in vitro and in vivo. SREBF1–ACSF2 axis nominated as therapeutic target. Topic: hematologic_malignancies · study: experimental mechanistic · species: AML cell lines + murine · evidence: preclinical
[42537584] Zhao J et al. · ESMO Open · 2026-07-31 · Score: 7
MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma.
Prospective cohort (NICHE trial, n=227 NDMM). MYC-R is an independent PFS predictor (HR 1.96, p=0.007). Adding MYC-R to the double-hit model raises concordance index 0.549 → 0.581. IgH/MYC fusion carries worst prognosis. Supports routine MYC-R inclusion in FISH panels for NDMM. Topic: hematologic_malignancies · study: prospective cohort · species: human clinical · evidence: prospective cohort
Novel Therapeutics (Immunotherapy / CAR-T / Targeted)
[42537705] Zhao C et al. · J Hepatol · 2026-07-31 · Score: 8
Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction.
snRNA-seq of post-TACE HCC reveals PDGFC+ TAM-driven immunosuppressive vascular niche. Low-dose Bev+Atezo corrects hypoxia, reduces PDGFC+ TAMs, enhances CD8+ T cells in preclinical models. Retrospective clinical analysis supports improved outcomes without hepatic function compromise after TACE. Direct translational rationale for combination therapy optimization. Topic: novel_therapeutics · study: translational (snRNA-seq + multi-cohort + retrospective clinical) · species: human specimens + HCC mouse models · evidence: translational/retrospective clinical
[42538152] Chen JY et al. · Gut · 2026-07-31 · Score: 8
Enhanced acetate uptake and metabolism in endothelial cells promote tumour angiogenesis and immunosuppression by increasing histone acetylation.
Hepatic acetate activates MCT1→ACSS2→H3K27ac axis in tumor endothelial cells, fueling angiogenesis and Treg expansion while exhausting CD8+ T cells. EC-targeting ACSS2 inhibition synergizes with anti-PD-1 in multiple mouse HCC models. Novel metabolic-epigenetic target for overcoming immune exclusion in HCC. Topic: novel_therapeutics · study: experimental (multiple mouse models) · species: human specimens + murine · evidence: preclinical with clinical specimens
[42538270] Tsugaru K et al. · EBioMedicine · 2026-07-31 · Score: 8
d-serine as a metabolic immune checkpoint in the tumour microenvironment.
Novel discovery: D-amino acid d-serine acts as a metabolic immune checkpoint in GI cancers. scRNA-seq + organoid allografts + microbiome manipulation demonstrates D-serine reshapes tumor-infiltrating immune cells, modulating macrophage-T cell interactions. Clinical correlates in GI cancer patients. Entirely new class of metabolic checkpoint with microbiome-tractable therapeutic potential. Topic: novel_therapeutics · study: translational (scRNA-seq + organoids + microbiome) · species: murine + organoid allografts · evidence: preclinical with clinical data
[42538053] Zhang H et al. · J Immunother Cancer · 2026-07-31 · Score: 7
CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3-TGF-β signaling pathway.
Identifies CPNE1 as a novel CAR-T resistance mechanism in HCC via STAT3-TGF-β-mediated T-cell exhaustion. CPNE1 knockdown restores GPC3 CAR-T efficacy and enhances intratumoral T-cell infiltration in preclinical models. High CPNE1 inversely correlates with T-cell infiltration and ICI outcomes clinically. CPNE1-STAT3-TGF-β axis nominated as combinatorial target. Topic: novel_therapeutics · study: experimental mechanistic · species: HCC cell lines + murine · evidence: preclinical
[42537452] Talor E et al. · Oral Oncol · 2026-07-31 · Score: 7 (Phase 3 RCT)
A novel neoadjuvant immunotherapy confers improved overall survival in oral cancer patients with low tumor PD-L1 expression: The IT-MATTERS Clinical trial.
Phase 3 RCT (NCT01265849). LI+CIZ+SOC vs SOC in cN0 + PD-L1 TPS <10% OSCC: OS HR 0.26 (p=0.0023), 32% absolute 5-year survival advantage, PFS HR 0.43 (p=0.0178). Striking results in a PD-L1-low population typically refractory to immunotherapy. LI+CIZ engages a distinct neoadjuvant immunostimulatory pathway. Topic: novel_therapeutics · study: phase 3 RCT · species: human clinical · evidence: phase 3 RCT
Precision Oncology
[42537645] Rachamala HK et al. · Cell Rep · 2026-07-31 · Score: 7
AI-driven discovery and validation of a GIPC1 PDZ domain inhibitor for pancreatic ductal adenocarcinoma.
AI/ML-driven drug discovery unlocks the previously undruggable GIPC1 PDZ domain in PDAC. GIPCi confirmed via HDX-MS direct binding. GIPCi alone or with gemcitabine suppresses PDAC tumor growth in patient-derived organoids and xenograft models. Demonstrates AI-to-drug preclinical pipeline for chemoresistant PDAC (<13% 5-year survival). Topic: precision_oncology · study: AI + experimental (in vitro + in vivo) · species: PDAC lines + PDO + xenograft · evidence: preclinical
Rare Diseases
[42538546] Schoser B · Orphanet J Rare Dis · 2026-07-28 · Score: 7
Defining the therapeutic corridor of stability in enzyme replacement therapy for Pompe disease: a position statement.
First quantitative monitoring framework for Pompe disease ERT (3 approved agents). Defines therapeutic corridor of stability: FVC within −1% to +5%/year (alarm >5% decline/12mo), 6MWT within ±25m of peak (action >25m decline), uHex-4 and CK normalization as early surrogates. Synthesizes Phase 2/3 RCTs + registries + real-world switching studies. Actionable for clinical practice. Topic: rare_diseases · study: systematic review + position statement · species: human clinical · evidence: synthesis of Phase 2/3 RCTs + real-world
🟡 MEDIUM PRIORITY (score 5–6)
Hematologic Malignancies
| PMID | Score | Article |
|---|---|---|
| [42537846] | 6 | Frigault MJ et al. CRS/ICANS incidence with axi-cel/brexu-cel: CIBMTR real-world data (n=927, 87 US centers). CRS 82.6%, ICANS 48.4%; evolving preventive management. Transplant Cell Ther. |
| [42537695] | 6 | Bashir Q et al. Evomela Phase I/II for ASCT in myeloma. MRD-neg sCR/CR 45% at D90; higher melphalan AUC → deeper response (PBE=0.99); improved PFS vs MEL200. Blood Adv. |
| [42538564] | 5 | Voran JC et al. CAR-T cancer treatment-related cardiovascular toxicity per 2022 ESC definitions (n=104). First ESC-framework characterization of CTR-CVT in CAR-T patients. Cardiooncology. |
Early Cancer Detection
| PMID | Score | Article |
|---|---|---|
| [42536239] | 6 | Sato M et al. Urine cfDNA for IPMN diagnosis (prospective, n=33). Urine KRAS detection 58% vs plasma 19%; GNAS+KRAS positivity OR 8.10 for malignancy. Non-invasive pancreatic precancer liquid biopsy. Ann Surg Oncol. |
AI/ML Diagnostics
| PMID | Score | Article |
|---|---|---|
| [42537009] | 6 | Li X et al. ML for sleep apnea via EEG: SR+MA (27 studies). Pooled AUROC 0.95 at segment level; deep learning outperforms traditional ML; near-absence of patient-level validation limits clinical translation. JMIR. |
| [42536993] | 5 | Swillens JEM et al. Delphi consensus on minimum requirements for CPath algorithm for tumor budding in CRC (n=59 pathologists, 72% consensus). Practical roadmap for CPath adoption. JCO Clin Cancer Inform. |
| [42536998] | 5 | Wang HJ et al. ML for postoperative vomiting prediction (n=33,460). LightGBM AUC 0.729 (vs Apfel 0.610); controlled LLM framework for normalization/explainability. Internal validation only. JMIR Med Inform. |
| [42538544] | 5 | Shamsabadi MA et al. LLMs (GPT-5.2, Gemini 3, Copilot, Claude Opus 4.1) vs EM physicians in diagnostic reasoning: LLMs 73.75% vs physicians 57.0%; LLMs stable across definitive/differential. Preliminary (10 vignettes). Int J Emerg Med. |
Precision Oncology
| PMID | Score | Article |
|---|---|---|
| [42537468] | 5 | Wu W et al. Oxypeucedanin/KIF11 degradation in LUAD via TRIM21/MCM2-CDK1 axis; PDO + xenograft validation. Natural compound, uncertain clinical pathway. Phytomedicine. |
| [42537395] | 5 | Välimäki E et al. NRAS-mutant conjunctival melanoma (ultra-rare): ex vivo MEK/RAS inhibitor sensitivity → clinical MEK inhibitor benefit; RAS(ON) inhibitors active. Biomed Pharmacother. |
| [42538280] | 5 | Kabirian R et al. ICI rechallenge in cervical/endometrial cancer (RICE study, 10 French centers, n=29 efficacy). ORR 52% on rechallenge vs 76% prior; PFS 6.0 vs 11.0 months; manageable toxicity. Int J Gynecol Cancer. |
Novel Therapeutics
No additional MEDIUM articles beyond HIGH-listed items.
Cardiovascular-Metabolic
| PMID | Score | Article |
|---|---|---|
| [42537913] | 6 | Shin SM et al. Serum ketone bodies + kidney outcomes in T2DM (prospective cohort, n=1392). Highest ketone tertile: aHR 0.46 for ≥40% eGFR decline; supports ketonemia as kidney-protective mechanism of SGLT2i. Diabetes Res Clin Pract. |
| [42538001] | 6 | Rudran B et al. GLP-1 RA + 90-day outcomes after THA/TKA: SR+MA (10 cohort studies, n=96,356). Surgical RR 0.73, medical complication RR 0.78, readmission RR 0.79. GRADE very low to moderate. Bone Joint J. |
| [42537842] | 6 | Nageswaran G et al. MASLD + Lp(a) + long-term outcomes in MESA. MASLD+elevated Lp(a): HR 2.07 for hard CVD; MASLD+low Lp(a): HR 1.28 all-cause mortality. First joint MASLD-Lp(a) analysis. Metabolism. |
| [42537430] | 5 | Zampieri FG et al. Dapagliflozin in critically ill AKI (DEFENDER post-hoc, n=212). No excess mortality or KRT; neutral safety profile. Supports feasibility of SGLT2i trials in AKI. J Crit Care. |
| [42538499] | 5 | Mohammed O, Kim SH et al. SGLT-2i in uncontrolled/resistant hypertension: pilot meta-analysis (4 RCTs, n=3718). SBP −3.3 mmHg; increased volume depletion/genital infections. Modest effect. High Blood Press Cardiovasc Prev. |
Aging & Longevity
| PMID | Score | Article |
|---|---|---|
| [42538413] | 5 | Li Y. Cross-species cardiac aging transcriptomics. Conserved cardiac aging niche score (CCANS) elevated in 2 human HF cohorts (Hedges g=1.04, p=6.3×10⁻⁵); inflammatory fibroblast signatures context-dependent. Funct Integr Genomics. |
| [42538330] | 5 | Manzoni V et al. Continuous-time hidden multistate models for multimorbidity trajectories. Reduces bias vs standard models; identifies mortality gradient in SNAC-K (n=2716, 18-year follow-up). Sci Rep. |
Rare Diseases
| PMID | Score | Article |
|---|---|---|
| [42535932] | 6 | Chen S et al. PhenoSS: Gaussian copula-based rare disease prediction from HPO with batch-effect correction. Validated on CHOP EHR; competitive disease prioritization; effective patient clustering. JAMIA. |
| [42533598] | 6 | Kulmala LM et al. Childhood aplastic anemia: population-based (Finland 2006–2020, n=52). Incidence 2.9/million/yr; OS 92.7%; 41% IST→HSCT; females have worse HRQoL. Pediatr Blood Cancer. |
Sentinel Scan
| PMID | Score | Article |
|---|---|---|
| [42538542] | 6 | Kebir S et al. TTFields initiated before/during RT in newly diagnosed GBM: Phase I/II feasibility (PriCoTTF, n=20). Zero treatment-limiting toxicities; median 76.5% adherence; median OS 18.0 months. Supports randomized evaluation of earlier TTFields integration. BMC Cancer. |
| [42538579] | 5 | Numan AT et al. Normothermic machine perfusion preserves endothelial clearance and modulates inflammation after prolonged warm ischemia in human liver grafts. Transplantation. |
⚪ LOW PRIORITY (score ≤ 4)
| PMID | Score | Topic | Article |
|---|---|---|---|
| [42537429] | 4 | AI_ML | MD-Mamba for breast histopathology (BACH dataset, AUC 0.9956); no external validation. Transl Oncol. |
| [42538450] | 4 | Hem | Exercise RCT in lymphoma (n=86): improved cognitive/fitness/QoL at 4wk. J Cancer Surviv. |
| [42534895] | 4 | Rare | Castleman disease 12-case series: clinical features, pathology, outcomes. Front Oncol. |
| [42535720] | 4 | Rare | Review: clinical pharmacology tools for rare disease drug development (model-informed PK/PD, adaptive designs). J Clin Pharmacol. |
| [42535129] | 4 | T3 | Improved FIT buffer: better Hb stability at 37°C for postal CRC screening (pilot, n=130 samples). J Anus Rectum Colon. |
| [42535923] | 4 | T3 | AI triage in breast cancer screening: reduced workload, noninferior detection, higher recall. Radiol Imaging Cancer. (Title-only — conservative cap applied.) |
| [42537828] | 4 | Prec Onc | SMG1/NMD-directed immunotherapy in HCC: critical review. Single-author, no original data. Crit Rev Oncol Hematol. |
⚠️ Coverage Notes
| Topic | Hits | Status |
|---|---|---|
| Hematologic malignancies | 62 | ✅ 15 reviewed; 3 false positives excluded |
| CBC/ML diagnostics | 0 | ⛔ Zero results — both primary and fallback queries returned empty |
| Early cancer detection | 19 | ✅ 15 reviewed; 2 false positives excluded |
| AI/ML diagnostics | 26 | ✅ 15 reviewed; 1 false positive excluded |
| Precision oncology | 17 | ✅ 15 reviewed |
| Novel therapeutics | 52 | ✅ 15 reviewed |
| Cardiovascular-metabolic | 63 | ✅ 15 reviewed |
| Aging/longevity | 28 | ✅ 15 reviewed; 2 low-relevance excluded |
| Rare diseases | 8 | ✅ All 8 reviewed (below 15 cap) |
| Sentinel scan | 432 | ✅ 10 reviewed (cap applied) |
T2 (CBC/ML) gap: The "complete blood count AND machine learning" intersection yielded zero results on 2026-07-31 to 2026-08-01. This is expected for such a specific intersection over a single-day window. No fallback results; topic flagged as uncovered for this window. Monitor next run.
Generated by Friday (OpenClaw) · Attempt 1 · Schema v1.3 · 2026-08-01T09:00:00Z